Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Perspective Therapeutics
Modality
radiopharmaceutical
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04904120CT.gov Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Uveal Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| [203pb]vmt01 (this asset) | Perspective Therapeutics | P1 | CC · 47 |
| Ifa | Craig L Slingluff, Jr | P2 | BBB |
| Tyrosinase Peptide | University of Southern California | P3 | BB |
| Sargramostim | Thomas Jefferson University | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P2/3 | BB |
| Darovasertib | IDEAYA Biosciences | P3 | BB |
| Gm-Csf | Ahmad Tarhini | P2 | BB |
| Thalidomide | Memorial Sloan Kettering Cancer Center | P2 | BB |
| Pembrolizumab | BioInvent International AB | P2/3 | BB |
+42 more in the Uveal Melanoma cohort
Other indications for [203pb]vmt01
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P1/2 | CCC · 55 |
| Cutaneous Melanoma | — | P1/2 | CCC · 53 |
| Mucosal Melanoma | — | P1 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. [203pb]vmt01 in Uveal Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/203pbvmt01-uveal-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →